

Millennium Health Announces Expanded Pharmacogenetic Tests New Online Portal Helps Patients and Clinicians Access Information

Millennium Health announced today that it has added three new genes to its Millennium PGTSM menu. The company also launched DestinationWell.com, an online tool offering consumers information about pharmacogenetics and how these tests can help patients understand the role that genetics plays in determining which prescription medications are right for them.

“Everyone’s genetics are different, and the personalized medication intelligence Millennium provides helps clinicians put patients on the path to well sooner,” said Brock Hardaway, chief executive officer. “This means resources can be used more effectively, and ultimately it may help to reduce the \$300 billion in spending that results from the underuse, overuse and misuse of prescription drugs.”

Millennium PGT is a non-invasive genetic test that uses either a buccal or saliva-specimen to identify how a patient’s genetic profile may impact response to certain medications. The medication intelligence Millennium Health provides helps clinicians make more effective prescribing decisions personalized for each patient. The test results provide information to help clinicians determine the right drug and right dose for each patient.

Millennium PGT analyzes up to 14 genes and provides clinically actionable interpretation for a broad list of medications in four key therapeutic areas: chronic pain, mental health, addiction and cardiovascular. The three new genes offered include: DRD2 and HTR2C, relevant to antipsychotics and HLA-B*15:02, relevant to anticonvulsants. Millennium is the only pharmacogenetic test menu offering the unique combination of all three genes.

“The addition of these three genes and their corresponding medications enable us to offer more comprehensive testing options to our customers and the patients they treat,” said Jennifer Strickland, Millennium Health’s general manager of pharmacogenetic testing. “Millennium PGT provides evidence-based and guideline-driven information regarding clinically relevant gene-drug combinations.”

The Millennium Analysis of Patient Phenotype (MAPP®) Report provides clinicians with evidence-based and clinically actionable information to support medication decisions for over 40 commonly prescribed medications across 13 medication classes. The MAPP report is supported by published evidence, clinical guidelines, and recommendations in U.S. Food and Drug Administration approved medication labels.

Millennium’s new online site, Destination Well, provides vital information on how pharmacogenetic tests can assist clinicians in determining the right medication for their patients.

To view the site, go to www.destinationwell.com.